Biomarker Guided Prostate Cancer Management
The BioGuidePCa project is designed to address the European Market demand for a diagnostic test which enables distinguishing between insignificant and significant prostate cancer (PCa). The proposed test detects peptides indicative of PCa by capillary electrophoresis-mass spectrometry (CE-MS). The output of the project will be a non-invasive test, called the “PCa Status Test”, designed to guide the treatment decision-making for patients on active surveillance. This is not a clinical study.
1 012 970.00€
Biochemistry / Biophysics
Diagnostic test products and equipment